Clinical trials in patients with acute kidney injury (AKI) have been stymied by a lack of consensus on suitable renal-specific end points. In a recent analysis, Grams et al. suggest that a sustained 30–40% reduction in estimated glomerular filtration rate after hospital discharge might be a suitable intermediate end point for AKI clinical trials.
Refers to Grams, M. E. et al. Candidate surrogate end points for ESRD after AKI. J. Am. Soc. Nephrol.http://dx.doi.org/10.1681/ASN.2015070829